AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has entered into a licensing agreement with South Korea-headquartered...
Alteogen
Alteogen Secures Exclusive Licensing Deal with Daiichi Sankyo for Subcutaneous Enhertu
Alteogen Inc. (KOSDAQ: 196170), a South Korea-based biotechnology company, has announced an exclusive licensing agreement...
Daiichi Sankyo and Alteogen Sign $300 Million Deal to Develop Subcutaneous Enhertu
Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has entered into a potentially $300...